DURECT Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DURECT stock.
View analyst ratings for DURECT or view top-rated stocks.

DURECT's stock was trading at $0.9859 on January 1st, 2022. Since then, DRRX shares have decreased by 46.4% and is now trading at $0.5289.
View the best growth stocks for 2022 here.

DURECT saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 11,290,000 shares, a decrease of 14.5% from the May 15th total of 13,200,000 shares. Based on an average trading volume of 917,400 shares, the short-interest ratio is currently 12.3 days. Approximately 5.0% of the shares of the company are sold short.
View DURECT's Short Interest.

DURECT is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for DURECT.

DURECT Co. (NASDAQ:DRRX) posted its earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). The specialty pharmaceutical company had revenue of $1.92 million for the quarter, compared to analysts' expectations of $2.43 million. DURECT had a negative net margin of 270.27% and a negative trailing twelve-month return on equity of 60.89%. During the same quarter last year, the firm posted ($0.05) earnings per share.
View DURECT's earnings history.

Some companies that are related to DURECT include Radius Health (RDUS), Amryt Pharma (AMYT), COMPASS Pathways (CMPS), Altimmune (ALT), Protagonist Therapeutics (PTGX), Imago BioSciences (IMGO), Centessa Pharmaceuticals (CNTA), Nkarta (NKTX), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), Edgewise Therapeutics (EWTX), Arbutus Biopharma (ABUS), Karyopharm Therapeutics (KPTI), Esperion Therapeutics (ESPR) and Tango Therapeutics (TNGX).
View all of DRRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

DURECT's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.06%), Ingalls & Snyder LLC (3.18%), State Street Corp (1.75%), CM Management LLC (1.55%), Renaissance Technologies LLC (1.54%) and Beirne Wealth Consulting Services LLC (1.21%). Company insiders that own DURECT stock include Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito.
View institutional ownership trends for DURECT.

DRRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Ingalls & Snyder LLC, Goldman Sachs Group Inc., and Simplex Trading LLC. Company insiders that have sold DURECT company stock in the last two years include Judy R Joice, and Lp Bleichroeder.
View insider buying and selling activity for DURECT or view top insider-selling stocks.

DRRX stock was bought by a variety of institutional investors in the last quarter, including CM Management LLC, Renaissance Technologies LLC, Beirne Wealth Consulting Services LLC, Connor Clark & Lunn Investment Management Ltd., Eqis Capital Management Inc., Gagnon Securities LLC, State Street Corp, and Tobias Financial Advisors Inc.. Company insiders that have bought DURECT stock in the last two years include Gail M Farfel, Judith J Robertson, Mohammad Azab, and Simon X Benito.
View insider buying and selling activity for DURECT or or view top insider-buying stocks.

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRRX stock can currently be purchased for approximately $0.53.

DURECT (NASDAQ:DRRX) has a market capitalization of $120.46 million and generates $13.98 million in revenue each year. The specialty pharmaceutical company earns $-36.26 million in net income (profit) each year or ($0.16) on an earnings per share basis.

DURECT employs 79 workers across the globe.

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for DURECT is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at [email protected], or via fax at 408-777-3577.